- Home
- NWBI vs VRDN Comparison
NWBI vs VRDN Comparison
Compare NWBI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWBI | VRDN |
|---|---|---|
| Founded | 1896 | 2006 |
| Country | United States | United States |
| Employees | 2233 | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2009 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NWBI | VRDN |
|---|---|---|
| Price | $15.30 | $21.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $14.50 | ★ $35.46 |
| AVG Volume (30 Days) | 835.9K | ★ 1.1M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.82% | N/A |
| EPS Growth | ★ 16.46 | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $6.29 | $13.73 |
| Revenue Next Year | $5.06 | $279.00 |
| P/E Ratio | $21.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.25 | $13.18 |
| 52 Week High | $16.16 | $34.29 |
Technical Indicators
Market Signals| Indicator | NWBI | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 44.21 |
| Support Level | $15.07 | $21.40 |
| Resistance Level | $15.63 | $23.84 |
| Average True Range (ATR) | 0.26 | 0.90 |
| MACD | -0.01 | -0.23 |
| Stochastic Oscillator | 43.70 | 18.30 |
Price Performance
Historical ComparisonAbout NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution, offering personal and commercial banking solutions, business services, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and Commercial Banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Commercial Banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.